BG 00011

Drug Profile

BG 00011

Alternative Names: BG-00011; STX-100

Latest Information Update: 01 Oct 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Biogen Idec
  • Developer Biogen
  • Class Antifibrotics; Monoclonal antibodies
  • Mechanism of Action Integrin alphaVbeta6 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Fibrosis; Idiopathic pulmonary fibrosis
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Idiopathic pulmonary fibrosis

Most Recent Events

  • 21 Sep 2018 Phase-II clinical trials in Idiopathic pulmonary fibrosis (In the elderly, In adults) in Australia (SC) (NCT03573505)
  • 21 Sep 2018 Biogen initiates the phase II SPIRIT trial in Idiopathic pulmonary fibrosis (In the elderly, In adults) in USA (SC) (NCT03573505)
  • 18 May 2018 Interim adverse events and pharmacokinetics data of a phase II trial in idiopathic pulmonary fibrosis presented at the 114th International Conference of the American Thoracic Society (ATS-2018)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top